Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2018 Jun 14;17(4):630–637.e8. doi: 10.1016/j.cgh.2018.05.059

Table 2.

Diagnostic performance of MRE and VCTE for the detection of liver fibrosis

Overall
(n=230)		 AUROC
(95%CI)		 Optimal
Threshold
(kPa)		 Sensitivity
(%)		 Specificity
(%)		 PPV
(%)		 NPV
(%)		 TE versus
MRE P-value
Stage 1–4 (n=157) versus 0 (n=73)
    MRE 0.8685
(0.8230–0.9139)		 2.61 71.3 72.6 84.9 54.1 0.0394
    TE 0.8184
(0.7610–0.8759)		 6.2 65.6 67.1 81.1 47.6
Stage 2–4 (n=93) versus 0–1 (n=137)
    MRE 0.9193
(0.8826–0.9560)		 2.97 84.9 85.4 79.8 89.3 0.0265
    TE 0.8664
(0.8184–0.9144)		 7.6 76.3 79.6 71.7 83.2
Stage 3–4 (n=57) versus 0–2 (n=173)
    MRE 0.9295
(0.8948–0.9641)		 3.62 82.5 83.2 61.8 93.5 0.0004
    TE 0.8411
(0.7805–0.9016)		 8.8 77.2 78.0 53.7 91.2
Stage 4 (n=25) versus 0–3 (n=205)
    MRE 0.9423
(0.8920–0.9927)		 4.7 80.0 85.9 40.8 97.2 0.0046
    TE 0.8357
(0.7351–0.9364)		 11.8 80.0 81.0 33.9 97.1